← Leaderboards
Alan J Fischman
Massachusetts General Hospital
$7,064,039
Attributed
$7,064,039
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $679.6K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$7,064,039 · 9
By mechanism
P50$4,827,980 · 4
M01$1,205,183 · 2
T32$1,002,428 · 1
P51$28,448 · 2
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Ronald Gary Tompkins$30,467,584
- Jeevendra Martyn$10,698,401
- Raul Mostoslavsky$11,553,356
- Corrine K Welt$6,308,123
- Michael R Hamblin$6,140,037
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPositron Emission TomographyClinical ResearchClinical Trial Phase ITissuesGlucose MetabolismTrauma CentersComplexFundingGene ExpressionBurn TraumaDesignPositron-Emission TomographyProgramsPhysiologicalMitochondriaSkeletal Muscle StructureBloodInstructionBioimaging /Biomedical ImagingAnimalsFutureStable IsotopeMolecular Imaging
Grant awards (39)
Core C: PET and Mass Spectroscopy Core$423,328
P50 · FY2017 · GM · contact PI
Project 2: Drug therapy to ameliorate mitochondrial dysfunction$256,274
P50 · FY2017 · GM · contact PI
Core C: PET and Mass Spectroscopy Core$423,328
P50 · FY2016 · GM · contact PI
Project 2: Drug therapy to ameliorate mitochondrial dysfunction$256,274
P50 · FY2016 · GM · contact PI
Core C: PET and Mass Spectroscopy Core$317,089
P50 · FY2015 · GM · contact PI
Project 2: Drug therapy to ameliorate mitochondrial dysfunction$221,082
P50 · FY2015 · GM · contact PI
Core C: PET and Mass Spectroscopy Core$374,813
P50 · FY2014 · GM · contact PI
Project 2: Drug therapy to ameliorate mitochondrial dysfunction$232,820
P50 · FY2014 · GM · contact PI
Core C: PET and Mass Spectroscopy Core$423,328
P50 · FY2013 · GM · contact PI
Project 2: Drug therapy to ameliorate mitochondrial dysfunction$256,274
P50 · FY2013 · GM · contact PI
Tissue-Specific Metabolic Response to Injury$310,872
P50 · FY2008 · GM · contact PI
Pet Core Facility$125,658
P50 · FY2008 · GM · contact PI
Tissue-Specific Metabolic Response to Injury$329,065
P50 · FY2007 · GM · contact PI
Research Training in Nuclear Molecular Imaging$192,728
T32 · FY2007 · EB · contact PI
Pet Core Facility$133,019
P50 · FY2007 · GM · contact PI
Tissue-Specific Metabolic Response to Injury$176,790
P50 · FY2006 · GM · contact PI
Research Training in Nuclear Molecular Imaging$175,183
T32 · FY2006 · EB · contact PI
Pet Core Facility$71,462
P50 · FY2006 · GM · contact PI
Research Training in Nuclear Molecular Imaging$251,098
T32 · FY2005 · EB
Tissue-Specific Metabolic Response to Injury$176,790
P50 · FY2005 · GM
Pet Core Facility$71,462
P50 · FY2005 · GM
Research Training in Nuclear Molecular Imaging$260,710
T32 · FY2004 · EB
Tissue-Specific Metabolic Response to Injury$176,790
P50 · FY2004 · GM
Pet Core Facility$71,462
P50 · FY2004 · GM
Research Training in Nuclear Molecular Imaging$122,709
T32 · FY2003 · EB
BRAIN SPECT IMAGING TO DETECT PARKINSONISM IN PATIENTS WITH MOVEMENT DISORDERS$14,224
P51 · FY2003 · RR
TEST-RETEST RELIABILITY OF 123I-ALTROPANE BINDING POTENTIAL IN MONKEYS$14,224
P51 · FY2003 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$200,768
M01 · FY2002 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$200,768
M01 · FY2002 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$200,768
M01 · FY2002 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$200,768
M01 · FY2002 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$200,768
M01 · FY2001 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$200,768
M01 · FY2001 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$0
M01 · FY2001 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$0
M01 · FY2001 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$575
M01 · FY2000 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$0
M01 · FY2000 · RR
CNS 5-HT1 Receptor Occupancy of Oral CP-361,428--PET Study$0
M01 · FY2000 · RR
PHARMACODYNAMICS OF BMS 204352 IN STABLE CEREBROVASCULAR DISEASE$0
M01 · FY2000 · RR